Boehringer Ingelheim, Cologne University Hospital (UKK), University of Marburg (UMR) and the German Center for Infection Research (DZIF) have initiated Phase I/IIa clinical investigation of novel SARS-CoV-2 neutralising antibody, BI 767551.

A potent anti-SARS-CoV-2 antibody, BI 767551 (DZIF-10c) has demonstrated promising virus neutralising properties in pre-clinical studies.

Merging UKK, UMR and DZIF’s expertise in virology, immunology and clinical investigation with Boehringer Ingelheim’s capabilities in developing and manufacturing therapeutic antibodies, BI 767551 was developed as a potential new therapeutic and preventive/prophylactic option for Covid-19.

To be led by UKK professors Florian Klein and Gerd Fätkenheuer, the study will be supplied with the antibody by Boehringer Ingelheim.

The Phase I/IIa studies will analyse the safety, pharmacokinetics and antiviral activity of the antibody. The first patients for the study have been enrolled.

In Phase I part of the study, participants will be given a single infusion or a single inhalation of the antibody.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Late-stage confirmatory studies will be conducted if BI 767551 is observed to be well tolerated.

Boehringer Ingelheim Innovation Unit Board of Managing Directors member Michel Pairet said: “We are excited to contribute to the development of BI 767551 in collaboration with our partners, with the aim to provide an innovative SARS-CoV-2 neutralising antibody, combining a systemic with an inhaled route of administration.”

University of Marburg Institute of Virology Director and DZIF Emerging Infections coordinator Prof Stephan Becker said: “Monoclonal antibodies are a promising component in the fight against new viruses, such as the SARS-CoV-2.

“If this antibody turns out to be effective against COVID-19, this finding could be helpful in the current and also in future epidemics and pandemics.”

Last month, the Icahn School of Medicine at Mount Sinai, Department of Medicine’s Clinical Trials Office and Boehringer Ingelheim enrolled the first patient to evaluate nintedanib in adult patients with acute lung injury following Covid-19 infection.